| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chi-Un Pae, Ashwin A Patka. Paroxetine: current status in psychiatry. Expert review of neurotherapeutics. vol 7. issue 2. 2007-02-27. PMID:17286545. |
paroxetine is the most potent inhibitor of the reuptake of serotonin among the available ssris. |
2007-02-27 |
2023-08-12 |
Not clear |
| F Chenu, E Dailly, M Bouri. Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 3. 2007-02-26. PMID:16757155. |
it could then be suggested that antidepressant-like effect of selective serotonin reuptake inhibitors (paroxetine and citalopram) in the mice fst requires the activation of dopaminergic pathways to occur. |
2007-02-26 |
2023-08-12 |
mouse |
| Sophie Robert, Mark B Hamner, Helen G Ulmer, Jeffrey P Lorberbaum, Valerie L Durkalsk. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. The Journal of clinical psychiatry. vol 67. issue 10. 2007-02-23. PMID:17107242. |
selective serotonin reuptake inhibitors (ssris) are considered first-line medication treatment, with sertraline, paroxetine, and fluoxetine being the most studied. |
2007-02-23 |
2023-08-12 |
Not clear |
| Laura Bazzichi, Gino Giannaccini, Laura Betti, Giovanni Mascia, Laura Fabbrini, Paola Italiani, Francesca De Feo, Tiziana Giuliano, Camillo Giacomelli, Alessandra Rossi, Antonio Lucacchini, Stefano Bombardier. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis research & therapy. vol 8. issue 4. 2007-02-20. PMID:16790074. |
sert expression and functionality were evaluated through the measurement of [3h]paroxetine binding and the [3h]serotonin uptake itself. |
2007-02-20 |
2023-08-12 |
human |
| M Rosetti, M Frasnelli, A Tesei, W Zoli, M Cont. Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. Journal of experimental therapeutics & oncology. vol 6. issue 1. 2007-02-15. PMID:17228521. |
in this work, we have compared two ssris, one very specific for serotonin reuptake transporters (paroxetine) and another which also inhibit norepinephrine and dopamine transporters (venlafaxine), for their ability to counteract growth of various murine and human cancer cell lines. |
2007-02-15 |
2023-08-12 |
human |
| Yukihiro Hamada, Katsuichi Miyamoto, Yohei Inatsugi, Hidekazu Suzuki, Susumu Kusunok. [A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine]. Rinsho shinkeigaku = Clinical neurology. vol 46. issue 8. 2007-02-12. PMID:17154040. |
we present a first case of parkinson's disease with neuroleptic malignant syndrome by paroxetine, one of the selective serotonin reuptake inhibitor (ssri). |
2007-02-12 |
2023-08-12 |
Not clear |
| P Paruchuri, D Godkar, D Anandacoomarswamy, K Sheth, S Niranja. Rare case of serotonin syndrome with therapeutic doses of paroxetine. American journal of therapeutics. vol 13. issue 6. 2007-02-09. PMID:17122538. |
rare case of serotonin syndrome with therapeutic doses of paroxetine. |
2007-02-09 |
2023-08-12 |
Not clear |
| P Paruchuri, D Godkar, D Anandacoomarswamy, K Sheth, S Niranja. Rare case of serotonin syndrome with therapeutic doses of paroxetine. American journal of therapeutics. vol 13. issue 6. 2007-02-09. PMID:17122538. |
paroxetine (paxil) is a selective serotonin reuptake inhibitor (ssri) and anxiolytic that is approved to treat numerous mood disorders. |
2007-02-09 |
2023-08-12 |
Not clear |
| P Paruchuri, D Godkar, D Anandacoomarswamy, K Sheth, S Niranja. Rare case of serotonin syndrome with therapeutic doses of paroxetine. American journal of therapeutics. vol 13. issue 6. 2007-02-09. PMID:17122538. |
most cases of serotonin syndrome that have occurred with paroxetine administration are due to inadvertent drug interactions, most notably between ssris and monamine oxidase inhibitors, or intentional overdoses. |
2007-02-09 |
2023-08-12 |
Not clear |
| P Paruchuri, D Godkar, D Anandacoomarswamy, K Sheth, S Niranja. Rare case of serotonin syndrome with therapeutic doses of paroxetine. American journal of therapeutics. vol 13. issue 6. 2007-02-09. PMID:17122538. |
the authors present the case of an 80-year-old woman who presented with serotonin syndrome while on a therapeutic dose of paroxetine. |
2007-02-09 |
2023-08-12 |
Not clear |
| Ana M Catafau, Victor Perez, Pedro Plaza, Juan-Carlos Pascual, Santiago Bullich, Marina Suarez, Maria M Penengo, Iluminada Corripio, Dolors Puigdemont, Monica Danus, Javier Perich, Enric Alvare. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology. vol 189. issue 2. 2007-02-05. PMID:17033844. |
serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123i-adam spect study. |
2007-02-05 |
2023-08-12 |
Not clear |
| Juan José Berzas Nevado, María Jesús Villaseñor Llerena, Carmen Guiberteau Cabanillas, Virginia Rodríguez Robledo, Sierra Buitrag. Sensitive capillary GC-MS-SIM determination of selective serotonin reuptake inhibitors: reliability evaluation by validation and robustness study. Journal of separation science. vol 29. issue 1. 2007-02-01. PMID:16485715. |
fluoxetine, fluvoxamine, citalopram, sertraline and paroxetine belong to the newest and most important drug group termed selective serotonin reuptake inhibitors. |
2007-02-01 |
2023-08-12 |
Not clear |
| F Giuliano, J Bernabé, P Gengo, L Alexandre, P Clémen. Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine. The Journal of urology. vol 177. issue 1. 2007-01-26. PMID:17162096. |
dapoxetine was compared with paroxetine, the selective serotonin reuptake inhibitor of reference. |
2007-01-26 |
2023-08-12 |
rat |
| M Naoe, Y Ogawa, T Shichijo, K Fuji, T Fukagai, H Yoshid. Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer. Prostate cancer and prostatic diseases. vol 9. issue 3. 2007-01-25. PMID:16786037. |
in this study, we evaluated the efficacy of paroxetine (selective serotonin reuptake inhibitors (ssris)) for hf. |
2007-01-25 |
2023-08-12 |
Not clear |
| Noemi Eiser, Rosari Harte, Karvounis Spiros, Christopher Phillips, Michael T Isaa. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD. vol 2. issue 2. 2007-01-19. PMID:17136950. |
in a randomised, double-blind fashion, 28 depressed copd patients took a selective serotonin re-uptake inhibitor, paroxetine 20 mg daily, or matched placebo for 6 weeks. |
2007-01-19 |
2023-08-12 |
Not clear |
| Agneta Ekman, Charlotta Sundblad-Elverfors, Mikael Landén, Tomas Eriksson, Elias Eriksso. Low density and high affinity of platelet [3H]paroxetine binding in women with bulimia nervosa. Psychiatry research. vol 142. issue 2-3. 2007-01-12. PMID:16690136. |
in this study, the density and affinity of platelet serotonin transporters were assessed in 20 women meeting the dsm-iv criteria for bulimia nervosa and in 14 controls without previous or ongoing eating disorder using [(3)h]paroxetine as a ligand. |
2007-01-12 |
2023-08-12 |
Not clear |
| John Cookson, Inmaculada Gilaberte, Durisala Desaiah, Daniel K Kajdas. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. International clinical psychopharmacology. vol 21. issue 5. 2007-01-10. PMID:16877897. |
the nnts for selective serotonin reuptake inhibitors (fluoxetine or paroxetine, 20 mg/day) were around 7 for response, 11 for remission, and 8 for cgi-defined improvement. |
2007-01-10 |
2023-08-12 |
Not clear |
| Tao Xie, Liqiong Tong, Michael W McLane, George Hatzidimitriou, Jie Yuan, Una McCann, George Ricaurt. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 12. 2007-01-05. PMID:16452989. |
all drug treatments produced lasting reductions in 5-ht, 5-hiaa, and [(3)h]paroxetine binding, but no significant change in the density of a 70 kda band initially thought to correspond to the sert protein. |
2007-01-05 |
2023-08-12 |
Not clear |
| Toru Kobayashi, Kazuo Washiyama, Kazutaka Iked. Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine. Journal of pharmacological sciences. vol 102. issue 3. 2007-01-04. PMID:17072103. |
paroxetine is commonly used as a selective serotonin reuptake inhibitor for the treatment of depression and other psychiatric disorders. |
2007-01-04 |
2023-08-12 |
xenopus_laevis |
| F Chenu, B P Guiard, M Bourin, A M Gardie. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behavioural brain research. vol 172. issue 2. 2006-12-28. PMID:16806519. |
however, we found that increases in cortical 5-ht overflow caused by systemic injection of the selective serotonin reuptake inhibitor (ssri), paroxetine was higher in freely moving (c57bl/6x129sv) nk1-/- mutants than in wild-type nk1+/+ mice. |
2006-12-28 |
2023-08-12 |
mouse |